IKT – inhibikase therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics (IKT) was upgraded by LADENBURG THALM/SH SH to "strong-buy".
Inhibikase Therapeutics (IKT) is now covered by LADENBURG THALM/SH SH. They set a "buy" rating and a $4.00 price target on the stock.
Inhibikase Therapeutics (IKT) was upgraded by Lifesci Capital to "strong-buy".
Inhibikase Therapeutics (NASDAQ:IKT) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Form S-8 Inhibikase Therapeutics,
Form 10-K Inhibikase Therapeutics, For: Dec 31
Form 8-K Inhibikase Therapeutics, For: Mar 26
Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Cabell Christopher
Form 4 Inhibikase Therapeutics, For: Feb 21 Filed by: Aurentz Vincent
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.